May 1, 2006

Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects

Structured PICO

Does sibutramine alter sympathetic vasomotor tone in nondiabetic obese subjects?

Population

20 nondiabetic obese men and women, mean age 42 +/- 8 years, mean body mass index 35 +/- 3 kg/m2

Intervention

Sibutramine 15 mg per day for 5 days

Comparator

Matching placebo for 5 days (crossover design)

Outcome

Heart rate, blood pressure, and muscle sympathetic nerve activity (MSNA) at rest and in response to cold pressor testing and phenylephrine/nitroprusside infusionssurrogate

Sibutramine treatment profoundly and selectively reduces resting sympathetic nerve traffic and attenuates responsiveness to sympathetic stimuli in obese subjects.

Abstract

BACKGROUND: Sibutramine, a serotonin and norepinephrine transporter blocker, is used as adjunctive obesity treatment. Studies in healthy subjects suggested that sibutramine might have opposing effects on peripheral and central sympathetic activity; an increase in blood pressure has been claimed. Direct measurements of muscle sympathetic nerve activity (MSNA) in sibutramine-treated patients have not been conducted. METHODS AND RESULTS: Twenty nondiabetic obese men and women completed the study (mean body mass index, 35 +/- 3 kg/m2; mean age, 42 +/- 8 years). They were treated for 5 days with 15 mg sibutramine per day or matching placebo in a randomized, double-blind, crossover fashion. At the end of each intervention, heart rate, blood pressure, and MSNA were recorded. Patients underwent cold pressor testing and phenylephrine and nitroprusside infusions. RESULTS: The mean blood pressure (systolic/diastolic) was 118 +/- 13 mm Hg/70 +/- 9 mm Hg with placebo and 120 +/- 13 mm Hg/69 +/- 8 mm Hg with sibutramine (P = .29). The mean resting MSNA was 28 +/- 14 bursts/min with placebo and 12 +/- 10 bursts/min with sibutramine (P < .0001). Sibutramine attenuated the rise in blood pressure (25 +/- 9 mm Hg/9 +/- 9 mm Hg versus 31 +/- 12 mm Hg/14 +/- 9 mm Hg, P < .01) and MSNA (0.3 +/- 0.5 arbitrary units/min versus 1.0 +/- 1.1 arbitrary units/min, P = .01) in response to cold pressor testing. Baroreflex heart rate control was similar with sibutramine and with placebo. The sympathetic baroreflex was shifted such that at a given blood pressure, MSNA was substantially decreased (top, 44 +/- 1.23 bursts/min versus 58 +/- 2.99 bursts/min P < .001; center point, 65 +/- 0.32 mm Hg versus 67 +/- 0.81 mm Hg P < .05). CONCLUSIONS: Sibutramine treatment profoundly and selectively reduces sympathetic nerve traffic at rest and attenuates the responsiveness to sympathetic stimuli. Our data support the idea that sibutramine's peripheral sympathomimetic effect is counteracted by a central sympatholytic mechanism.

KI fragen

Bookmark